België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

rotop pharmaka gmbh - tetrofosmine (bis)tetrafluoroboraat 0,34 mg - eq. tetrofosmine 0,23 mg - kit voor radiofarmaceutisch preparaat - 0,23 mg - tetrofosmine (bis)tetrafluoroboraat 0.34 mg - technetium (99mtc) tetrofosmin

Europese Unie - Nederlands - EMA (European Medicines Agency)

janssen-cilag international nv - esketamine hydrochloride - depressieve stoornis - andere antidepressiva - spravato, in combinatie met een ssri of snri, is geïndiceerd voor de behandeling van volwassenen met-bestendig depressieve stoornis, die niet hebben gereageerd op ten minste twee verschillende behandelingen met antidepressiva in de huidige matige tot ernstige depressieve episode.

Europese Unie - Nederlands - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant adenovirus type 26 (ad26) encoding the glycoprotein (gp) of the ebola virus zaire (zebov) mayinga strain - hemorragische koorts, ebola - vaccins - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Europese Unie - Nederlands - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant modified vaccinia ankara bavarian nordic virus encoding the: ebola virus zaire (zebov) mayinga strain glycoprotein (gp); ebola virus sudan gulu strain gp; ebola virus taï forest strain nucleoprotein and the marburg virus musoke strain gp - hemorragische koorts, ebola - vaccins - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Europese Unie - Nederlands - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - taaislijmziekte - andere producten van het ademhalingssysteem - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Europese Unie - Nederlands - EMA (European Medicines Agency)

janssen-cilag international nv - rilpivirine - hiv-infecties - antivirale middelen voor systemisch gebruik - rekambys is indicated, in combination with cabotegravir injection, for the treatment of human immunodeficiency virus type 1 (hiv 1) infection in adults who are virologically suppressed (hiv-1 rna < 50 copies/ml) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the nnrti and ini class.

Europese Unie - Nederlands - EMA (European Medicines Agency)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vaccins - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. het gebruik van dit vaccin moet gebeuren in overeenstemming met officiële aanbevelingen.

Europese Unie - Nederlands - EMA (European Medicines Agency)

janssen-cilag international n.v.    - amivantamab - carcinoom, niet-kleincellige long - antineoplastische middelen - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Europese Unie - Nederlands - EMA (European Medicines Agency)

amgen europe bv - sotorasib - carcinoom, niet-kleincellige long - antineoplastische middelen - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.

Europese Unie - Nederlands - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - multiple myeloma - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.